{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:22:42Z","timestamp":1793125362252,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006221","name":"Cordis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006221","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.ahj.2010.11.001","type":"journal-article","created":{"date-parts":[[2011,2,10]],"date-time":"2011-02-10T05:45:08Z","timestamp":1297316708000},"page":"391-396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: Analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial"],"prefix":"10.1016","volume":"161","clinical-trial-number":[{"clinical-trial-number":"nct00433966","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Diaa A.","family":"Hakim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Dangas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Caixeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Nikolsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra J.","family":"Lansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Moses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimmer","family":"Claessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Sanidas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey D.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Magnus","family":"Ohman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven V.","family":"Manoukian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2010.11.001_bb0005","first-page":"242","article-title":"Severe thrombocytopenia after heparin therapy in a patient with unstable angina and recent stent implantation","volume":"46","author":"Sideris","year":"2005","journal-title":"Hellenic J Cardiol"},{"key":"10.1016\/j.ahj.2010.11.001_bb0010","doi-asserted-by":"crossref","first-page":"256","DOI":"10.7326\/0003-4819-115-4-256","article-title":"Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial","volume":"115","author":"Bovill","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2010.11.001_bb0015","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1161\/01.CIR.0000127867.41621.85","article-title":"Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting","volume":"109","author":"Merlini","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2010.11.001_bb0020","first-page":"73","article-title":"Acute profound thrombocytopenia after use of eptifibatide for coronary stenting","volume":"58","author":"Salengro","year":"2003","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2010.11.001_bb0025","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1067\/mhj.2000.106615","article-title":"Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb\/IIIa blockade","volume":"140","author":"Kereiakes","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2010.11.001_bb0030","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1136\/heart.86.6.e18","article-title":"Acute profound thrombocytopenia following angioplasty: the dilemma in the management and a review of the literature","volume":"86","author":"Makoni","year":"2001","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2010.11.001_bb0035","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1161\/01.CIR.99.22.2892","article-title":"Clinical significance of thrombocytopenia during a non\u2013ST-elevation acute coronary syndrome. The platelet glycoprotein IIb\/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience","volume":"99","author":"McClure","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2010.11.001_bb0040","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1592\/phco.23.3.374.32107","article-title":"Acute profound thrombocytopenia associated with eptifibatide therapy","volume":"23","author":"Nagge","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ahj.2010.11.001_bb0045","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0735-1097(94)90634-3","article-title":"Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction study group","volume":"23","author":"Harrington","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2010.11.001_bb0050","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1592\/phco.24.6.664.34732","article-title":"Clopidogrel-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after coronary artery stenting","volume":"24","author":"Manor","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ahj.2010.11.001_bb0055","first-page":"339","article-title":"Clopidogrel-associated autoimmune thrombocytopenic purpura","volume":"62","author":"Best","year":"2004","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2010.11.001_bb0060","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.amjcard.2005.04.005","article-title":"Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction","volume":"96","author":"Nikolsky","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2010.11.001_bb0065","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0735-1097(98)00252-6","article-title":"Occurrence and clinical significance of thrombocytopenia in a population undergoing high risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) study group","volume":"32","author":"Berkowitz","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2010.11.001_bb0070","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2010.11.001_bb0075","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/jama.297.6.591","article-title":"ACUITY Investigators. Routine upstream initiation vs deferred selective use of glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: the ACUITY trial","volume":"297","author":"Stone","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2010.11.001_bb0080","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes. The HORIZONS-AMI","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2010.11.001_bb0085","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2010.11.001_bb0090","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/CIRCULATIONAHA.108.827162","article-title":"Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice (sub-analysis of the CRUSADE registry)","volume":"119","author":"Wang","year":"2009","journal-title":"Circulation"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870310010094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870310010094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:55:23Z","timestamp":1762077323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870310010094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0002870310010094"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2010.11.001","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: Analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2010.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}